文献速递显微修复重建创面修复

高良姜素经SIRT1介导FOXO1去乙酰化抑制铁死亡改善皮瓣存活

Galangin enhances skin flap survival by inhibiting ferroptosis via SIRT1-mediated FOXO1 deacetylation.
PubMed 文献 · Burns · 2026-01-19

本研究探讨天然黄酮高良姜素(Gal)对缺血再灌注皮瓣坏死的作用。体外以HUVEC氧糖剥夺/复氧模拟I/R,体内用大鼠改良McFarlane皮瓣模型,结合网络药理学与分子对接。结果显示Gal经上调SIRT1、促进FOXO1去乙酰化抑制铁死亡,剂量依赖性提高皮瓣存活面积与血流灌注,并减轻氧化应激与炎症。

要点

  • Gal经SIRT1/FOXO1通路抑制铁死亡,改善皮瓣存活。
  • SIRT1抑制剂EX527可削弱Gal的体外保护作用。
  • 体内Gal剂量依赖性提高皮瓣存活面积与血流灌注。

核心结论

  • 高良姜素通过激活SIRT1/FOXO1通路抑制铁死亡、氧化应激和炎症,从而增强皮瓣存活。

研究设计与样本

  • 网络药理学与分子对接预测Gal与SIRT1的相互作用。
  • 体外采用HUVEC氧糖剥夺/复氧模拟缺血再灌注损伤,评估细胞活力与铁死亡,并用SIRT1抑制剂EX527和铁死亡抑制剂Ferrostatin-1验证机制。
  • 体内建立大鼠改良McFarlane皮瓣模型,Gal处理组与对照组比较皮瓣存活、血流灌注、组织学及SIRT1/FOXO1通路关键蛋白表达。

主要发现

  • 体外Gal通过抑制铁死亡保护HUVEC,上调SIRT1、促进FOXO1去乙酰化、增加下游蛋白表达并抑制脂质过氧化。
  • SIRT1抑制可削弱Gal的上述保护作用。
  • 体内Gal剂量依赖性显著增加皮瓣存活面积和血流灌注。
  • Gal抑制中性粒细胞浸润、降低MDA水平、提高SOD活性、抑制促炎细胞因子并激活抗铁死亡蛋白。

临床怎么用

  • 提示高良姜素可能作为改善皮瓣缺血再灌注损伤的潜在药物,机制涉及SIRT1/FOXO1介导的铁死亡抑制。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Skin flap necrosis due to ischemia-reperfusion (I/R) injury remains a major obstacle in plastic and reconstructive surgery. Galangin (Gal) is a natural flavonoid with potent antioxidant and anti-inflammatory properties; its effect on ischemic flap necrosis remains unclear. METHODS: Network pharmacology and molecular docking were used to predict the interaction between Gal and SIRT1. In vitro, human umbilical vein endothelial cells were subjected to oxygen-glucose deprivation/reperfusion to simulate I/R injury, and subsequent assessments of cell viability and ferroptosis were performed. The SIRT1 inhibitor EX527 and the ferroptosis inhibitor Ferrostatin-1 were used to verify the ferroptosis-related mechanisms. In vivo, a modified McFarlane skin flap model was created in rats. Gal-treated groups were compared to a control group to evaluate flap survival, blood perfusion, histological changes, and the expression of key proteins in the SIRT1/FOXO1 pathway. RESULTS: In vitro, Gal protected HUVECs by suppressing ferroptosis. Mechanistically, Gal upregulated SIRT1, promoted FOXO1 deacetylation, increased expression of downstream proteins and inhibited lipid peroxidation. These protective effects were diminished by SIRT1 inhibition. In vivo, Gal treatment significantly increased flap survival area and blood perfusion in a dose-dependent manner. It also suppressed neutrophil infiltration, reduced MDA levels, increased SOD activity, and inhibited pro-inflammatory cytokines and activate anti-ferroptosis proteins. CONCLUSIONS: Gal enhances skin flap survival by suppressing ferroptosis, oxidative stress, and inflammation via activation of the SIRT1/FOXO1 pathway.

来源:Burns,查看原文。版权归原作者所有。

引用

  1. Yang J, Wang A, Qi Z, et al. Galangin enhances skin flap survival by inhibiting ferroptosis via SIRT1-mediated FOXO1 deacetylation. Burns. 2026. PMID: 41579448. doi:10.1016/j.burns.2026.107872

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。